Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» September 2011
September 2011
Pfizer Ratings Cut for Failure to Reduce Wyeth-Takeover Debt
Pfizer Ratings Cut for Failure to Reduce Wyeth-Takeover Debt
Bloomberg
debt
Pfizer
Wyeth
M&A
Roche expects $10 billion sales for HDL drug
Roche expects $10 billion sales for HDL drug
Yahoo/Reuters
Roche
HDL therapy
Merck
dalcetrapib
Anacetrapib
Teva breaking ground on $300M Phila. distribution center
Teva breaking ground on $300M Phila. distribution center
Bizjournals.com
Teva Pharmaceuticals
distribution
Lilly receives positive European opinion on Alimta
Lilly receives positive European opinion on Alimta
Yahoo/AP
Europe
lung cancer
Alimta
Eli Lilly
Alexion Pharma on a High
Alexion Pharma on a High
Yahoo/Zacks.com
Alexion
Soliris
aHUS
atypical hemolytic uremic syndrome
Jefferies analyst upgrades Alkermes to 'buy' after completion of acquisition, move to Ireland
Jefferies analyst upgrades Alkermes to 'buy' after completion of acquisition, move to Ireland
Yahoo/AP
Alkermes
M&A
drug delivery
Elan
Teva buys rest of Japan venture from Kowa at $150M
Teva buys rest of Japan venture from Kowa at $150M
Marketwatch
Kowa
Japan
Teva Pharmaceuticals
M&A
Cancer Cost Swells, Risks Becoming ‘Unsustainable,’ Lancet Says
Cancer Cost Swells, Risks Becoming ‘Unsustainable,’ Lancet Says
Bloomberg
cancer
9 Big Pharmas With The Least Side Effects
9 Big Pharmas With The Least Side Effects
Seeking Alpha
Abbott Laboratories
AstraZeneca
Bristol-Myers Squibb
GSK
Eli Lilly
Merck
Novartis
Pfizer
Sanofi
Human Genome Spikes On Sales: Good Time To Consider Buying
Human Genome Spikes On Sales: Good Time To Consider Buying
Seeking Alpha
Human Genome Sciences
GSK
Benlysta
lupus
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »